Evismo and Lucerne University of Applied Sciences and Arts research heart health
Zurich/Lucerne - Innosuisse is making the launch of a project on the early detection of heart rhythm disturbances possible with 1.15 million Swiss francs. Within this research project, the Zurich-based eHealth startup evismo will develop algorithms for early diagnosis and treatment with the iHomeLab at the Lucerne University of Applied Sciences and Arts.
Evismo and the iHomeLab at the Lucerne University of Applied Sciences and Arts are together developing systems and algorithms for the early detection, and to some extent also prediction, of heart rhythm disturbances (arrhythmias). The Swiss innovation agency Innosuisse is supporting this project with 1.15 million Swiss francs.
Early diagnosis and treatment of atrial fibrillation, heart palpitations, and other disorders can help to prevent strokes. According to a press release from evismo, approximately 100,000 individuals in Switzerland are affected by the most common type of arrhythmia: atrial fibrillation. This figure is ten times higher for people over the age of 75. Evismo has been providing its long-term ECG diagnostic device, CardioFlex, to medical specialists and stroke centers for around three years.
Evismo Co-Founder Alexander Panos states: “With our long-term ECG service, we don't simply want to digitize today's ECG diagnostics, but rather integrate human and artificial intelligence”. A key part of the project is to identify the sex-specific differences found in arrhythmias, thereby closing a gap in the data and contributing to sex-specific diagnosis.
The iHomeLab at the Lucerne University of Applied Sciences and Arts is contributing its expertise in machine learning and a wide range of data analysis methods. Patric Eberle, head of the Active and Assisted Living research group at iHomeLab comments: “We […] are convinced that we can play a pioneering role in ECG diagnostics worldwide.”
